Moderna, Inc. $MRNA Shares Sold by Lake Hills Wealth Management LLC

Lake Hills Wealth Management LLC lessened its stake in Moderna, Inc. (NASDAQ:MRNA) by 50.4% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 6,913 shares of the company’s stock after selling 7,023 shares during the period. Lake Hills Wealth Management LLC’s holdings in Moderna were worth $1,331,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in the stock. BlackRock Inc. acquired a new position in Moderna in the second quarter worth $2,142,877,000. Capital World Investors bought a new stake in shares of Moderna during the 4th quarter valued at about $378,299,000. Theleme Partners LLP acquired a new stake in Moderna during the second quarter worth about $564,272,000. Merck & Co. Inc. bought a new position in Moderna in the second quarter worth about $161,642,545. Finally, Bamco Inc. NY bought a new position in Moderna in the second quarter worth about $139,317,000. 75.33% of the stock is currently owned by institutional investors.

Insider Activity

In other news, insider Shannon Klinger sold 3,471 shares of the firm’s stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $139.95, for a total value of $485,766.45. Following the completion of the sale, the insider owned 74,129 shares of the company’s stock, valued at $10,374,353.55. This trade represents a 4.47% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, President Stephen Hoge sold 40,281 shares of Moderna stock in a transaction on Tuesday, September 15th. The shares were sold at an average price of $146.07, for a total value of $5,883,845.67. Following the transaction, the president owned 1,562,029 shares in the company, valued at $228,165,576.03. This represents a 2.51% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 118,882 shares of company stock worth $16,862,280 over the last 90 days. 10.80% of the stock is owned by company insiders.

Moderna Price Performance

Shares of MRNA traded up $3.64 during trading hours on Wednesday, hitting $191.10. 7,801,236 shares of the company were exchanged, compared to its average volume of 11,987,094. The company has a debt-to-equity ratio of 0.09, a current ratio of 2.29 and a quick ratio of 2.18. The company has a market capitalization of $76.29 billion, a PE ratio of -23.94 and a beta of 1.09. The firm has a fifty day simple moving average of $131.05 and a 200-day simple moving average of $81.90. Moderna, Inc. has a one year low of $22.28 and a one year high of $212.22.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings results on Friday, July 31st. The company reported ($1.97) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.03) by $0.06. Moderna had a negative return on equity of 28.30% and a negative net margin of 141.43%.The firm had revenue of $145.00 million for the quarter, compared to analysts’ expectations of $102.93 million. During the same quarter last year, the business posted ($2.13) EPS. Moderna’s revenue was up 2.1% on a year-over-year basis. As a group, sell-side analysts predict that Moderna, Inc. will post -6.09 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on MRNA shares. Royal Bank Of Canada reissued a “sector perform” rating and set a $130.00 price target on shares of Moderna in a report on Wednesday, August 19th. Deutsche Bank Aktiengesellschaft began coverage on shares of Moderna in a research report on Friday, August 28th. They issued a “hold” rating on the stock. Brookline Capital Markets reaffirmed a “buy” rating on shares of Moderna in a report on Wednesday, August 19th. The Goldman Sachs Group increased their price objective on Moderna from $67.00 to $120.00 and gave the stock a “neutral” rating in a report on Wednesday, August 19th. Finally, CLSA raised shares of Moderna to an “outperform” rating in a research note on Friday, August 28th. Seven research analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and five have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Moderna presently has a consensus rating of “Hold” and an average price target of $78.17.

More Moderna News

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Moderna and Merck expanded a multi-year collaboration with Tempus to support potential commercialization of intismeran autogene (V940/mRNA-4157), an individualized neoantigen cancer therapy being tested with Keytruda in melanoma and other cancers. The agreement reinforces the commercial potential of Moderna’s personalized cancer-vaccine platform. Tempus Announces Multi-Year Collaboration with Moderna and Merck
• Positive Sentiment: Investor interest remains elevated ahead of the anticipated full Phase 3 melanoma-vaccine data readout. Moderna’s mRNA-4157 program, developed with Merck, is viewed as a key potential growth driver beyond COVID-19 vaccines. Moderna Surges as Full Melanoma Readout Nears
• Positive Sentiment: Moderna is scheduled to join the Nasdaq-100 before the October 9 open, potentially increasing demand from index-tracking funds and boosting visibility. Moderna Stock Soars Ahead of Nasdaq-100 Return
• Neutral Sentiment: Coverage of Moderna’s manufacturing strategy highlighted lessons from its COVID-era production scale-up. Separately, researchers described an experimental AI-assisted approach that could reduce cold-storage requirements for mRNA vaccines, a potentially useful industry development but not an immediate Moderna-specific catalyst. CPHI 2026: Moderna Builds on Its COVID-Era Manufacturing Lessons
• Negative Sentiment: Morgan Stanley raised its price target to $95 but retained an “equal weight” rating, leaving substantial downside relative to the current market price. Analysts and market commentators are increasingly warning that Moderna’s surge—reported at roughly 545% year to date—may have outpaced fundamentals. Moderna Is Up 545% in 2026

Moderna Profile

Moderna, Inc is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can help prevent or treat disease, supporting the company’s work across infectious diseases, immuno-oncology, rare diseases, autoimmune conditions, and cardiovascular diseases.

Moderna’s commercial products include Spikevax, an mRNA vaccine for COVID-19, and mRESVIA, an mRNA vaccine for respiratory syncytial virus (RSV) in older adults.